Cancer

News

FDA approves GSK's Blenrep for advanced multiple myeloma

The FDA has approved GlaxoSmithKline’s multiple myeloma drug Blenrep, a first-in-class potential blockbuster that will be used in advanced disease.

News

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope to provide a more convenient alternative to expensive and cumberso

News

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for

News

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...

Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs.

News

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England.

News

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r

FDA approves GSK's Blenrep for advanced multiple myeloma

Incyte/Morphosys take on CAR-Ts with $198,000 per year antib...

Roche's NTRK tumour-agnostic therapy Rozlytrek approved in E...

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...

NICE backs kidney cancer combination from Merck KGaA and Pfi...

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks